PAH Clinical Scenarios: Advances in Diagnostic Assessment, Guideline-Recommended Care, and Emerging Treatments
Released On
March 30, 2023
Expires On
March 30, 2024
Media Type
Internet
Completion Time
75 minutes
Specialty
Acute Care, Cardiology, Critical Care, Emergency Medicine, Hospitalist, Primary Care, Pulmonology
Topic(s)
Acute Coronary Syndrome, Acute Heart Failure, Cardiovascular Disease, Heart, Heart Failure, Lung Disease
Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
Supported by an educational grant from Merck Sharpe & Dohme LLC.
Credit Available
- Physicians — maximum of 1.25 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is designed for pulmonologists and cardiologists, primarily, as well as physicians in internal medicine, primary care, and family medicine, physician assistants, nurse practitioners, and other healthcare providers who may be involved in managing care for patients with pulmonary arterial hypertension (PAH).
Program Overview
PAH is a rare, life-threatening disorder characterized by elevated pressure in the pulmonary arteries that quickly progresses to right ventricular failure and premature death. Expert consensus recommends early diagnosis and immediate treatment to improve survival in this mostly younger adult patient population. However, because PAH is an orphan disease with nonspecific presenting symptoms such as dyspnea, fatigue, weakness, heart palpitations, edema, and/or syncope, diagnosis is a challenge. In addition to knowing how to recognize and diagnose PAH, physicians must also be able initiate appropriate therapeutic strategies, generally combination therapies using multiple drug classes, and be aware of emerging treatment modalities to optimize outcomes.
Join experts Dr. John Ryan and Dr. Vallerie McLaughlin for this interactive on-demand video presentation about diagnosing, assessing, and managing PAH with optimal combination strategies of currently available and emerging treatments.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the signs and symptoms of PAH
- Identify assessment tools used to aid in the diagnosis and prognosis of PAH
- Incorporate guideline-recommended care for patients with PAH considerate of current and recently approved therapeutic options
- Evaluate the efficacy and safety of emerging therapeutic options for PAH
Faculty
Vallerie V. McLaughlin, MD
Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine
Interim Chief Clinical Officer, Ambulatory Care
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, Michigan
John J. Ryan, MD, MB, BCh, BAO
Associate Professor, University of Utah
Director, Pulmonary Hypertension Comprehensive Care Center
Director, Cardiovascular Medicine Fellowship Program
Interim Chief of General Cardiology
University of Utah Hospital
Faculty Director of Cardiology Education
University of Utah School of Medicine
Salt Lake City, Utah
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
- Vallerie V. McLaughlin, MD
- Grant Support Consultant: Aerovate, Altavant, Gossamer-Bio, Janssen, Merck, Sunovion
- Scientific Consulting: Aerami, Aerovate, Altavant, Bayer, Caremark, Corvista, Gossamer-Bio, Janssen, Merck, United Therapeutics
- John J. Ryan, MD, MB, BCh, BAO
- Grant Support Consultant: Gossamer-Bio, Janssen, Merck
- Scientific Consulting: Bayer, Janssen, Merck, United Therapeutics
The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Directions to Learners
There are no fees for participating and receiving CME credit for this activity. During the period of March 30, 2023 through March 30, 2024, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.